Quince Therapeutics Stockholders Approve Equity Plans and Share Increase
Quince Therapeutics, Inc. held a special meeting of stockholders where key proposals were approved. The company's 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan received stockholder approval, establishing initial share reserves and future automatic increases. Additionally, stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized common shares and approved the issuance of shares related to convertible preferred stock and warrants, which may result in a change of control.
Key Highlights
- Quince Therapeutics stockholders approved the 2026 Equity Incentive Plan with an initial share reserve of 821,872 shares plus additional shares from prior plans.
- The 2026 Employee Stock Purchase Plan was approved with an initial reserve of 142,045 shares.
- The number of authorized shares of common stock was increased from 250,000,000 to 275,000,000.
- Stockholder approval was granted for the issuance of shares upon conversion of Series C Convertible Preferred Stock and exercise of warrants/options, potentially exceeding 20% of outstanding shares.
Price Impact
More from QNCX
Quince Therapeutics Announces Conditional CEO, CFO, COO Appointments
Quince Therapeutics Files Orphai Acquisition Financials & Business Update
Quince Therapeutics Forms Scientific Advisory Board for LAM-001 Development